Impact of Leucovorin Shortage: A Comparison of Standard-Dose Versus Reduced-Dose Leucovorin in Metastatic Colorectal Cancer
JCO Global Oncology · 2026
DOI: 10.1200/go-26-00140 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JCO Global Oncology, 2026. Verfasst von Jude Howaidi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Leucovorin, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The frequent global shortage of leucovorin has raised several concerns. A guided approach is lacking in the guidelines. Data comparing standard-dose (400 mg/m 2 ) and reduced-dose (200 mg/m 2 ) leucovorin, both administered once on day 1 of each cycle, are unavailable. We plan to assess the efficacy and safety of leucovorin-containing regimens for standard and reduced doses in metastatic colorectal cancer (mCRC). METHODS This retrospective/prospective observational study was conducted at a tertiary hospital in Saudi Arabia and included data from 2020 to 2025. Adults with mCRC treated with a leucovorin-containing regimen were included. Because of frequent leucovorin shortages, the dose was reduced to 200 mg/m 2 intravenously given once on day 1 of each cycle. Patients were divided into two groups: leucovorin-400 and leucovorin-200. The study end points were progression-free survival (PFS), response rate, overall survival (OS), and safety. RESULTS A total of 99 patients were included (50 in the leucovorin-200 group and 49 in the leucovorin-400 group). The FOLFOX6 protocol was given to 67.3% of the overall population. The median PFS was 8 months for the leucovorin-200 group (95% CI, 5.8 to 12.6) and 8.1 months for the leucovorin-400 group (95% CI, 3.9 to 16.3; P = .943). Regarding response, 69.3% progressed with leucovorin-400 and 64% with leucovorin-200. The median OS was 71 months in the leucovorin-200 group and was not reached in the leucovorin-400 group ( P = .336). The incidence of adverse events was similar between the two groups except for grade 1 diarrhea, which occurred in 51% with leucovorin-400 and 18.4% with leucovorin-200 ( P = .001). A total of 1,180 vials were spared after changing the protocol, which correlates with 62,699 Saudi Riyal spared. CONCLUSION The choice between standard-dose and reduced-dose leucovorin may not affect outcomes in the metastatic setting. The reduced dose is a reasonable alternative in cases of drug shortage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia.
- Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia.
- Research Center, Research Services & Clinical Trial Administration, Scientific Writing & Biostatistics Department, King Fahad Medical City, Riyadh, Saudi Arabia.
- Department of Pharmacy, OncoClinicas, Riyadh, Saudi Arabia.
- Department of Pharmacy Practice, AlFaisal University, Riyadh, Saudi Arabia.
ORCID-Profile: Jude Howaidi, Fouad Alnajjar, Ahmed S Alanazi
Zitieren
APA
Howaidi, J., Alnajjar, F., Abu Alnasr, R., Alanazi, A. S., Alhumaid, M., Salman Bashir, M., & AlRajhi, A. M. (2026). Impact of Leucovorin Shortage: A Comparison of Standard-Dose Versus Reduced-Dose Leucovorin in Metastatic Colorectal Cancer. JCO Global Oncology. https://doi.org/10.1200/go-26-00140
Vancouver
Howaidi J, Alnajjar F, Abu Alnasr R, Alanazi AS, Alhumaid M, Salman Bashir M, et al. Impact of Leucovorin Shortage: A Comparison of Standard-Dose Versus Reduced-Dose Leucovorin in Metastatic Colorectal Cancer. JCO Global Oncology. 2026. doi:10.1200/go-26-00140
BibTeX
@article{Howaidi2026,
author = {Howaidi, Jude and Alnajjar, Fouad and Abu Alnasr, Rawan and Alanazi, Ahmed S and Alhumaid, Muhned and Salman Bashir, Muhammad and AlRajhi, Abdullah M},
title = {Impact of Leucovorin Shortage: A Comparison of Standard-Dose Versus Reduced-Dose Leucovorin in Metastatic Colorectal Cancer},
journal = {JCO Global Oncology},
year = {2026},
doi = {10.1200/go-26-00140}
}
EUVIMED